DENTSPLY SIRONA Inc.
No enriched coverage for $XRAY in the last 7 days.
No SEC Form 4 filings for $XRAY in the last 30 days.
See all $XRAY insider activity →Dentsply Sirona reported a Q2 2026 profit of $37M, reversing a $45M loss from the prior year, despite a 4.1% sales decline to $898M. Gross margin improved to 54.9%, and operating cash flow doubled to $99M. The company's turnaround plan aims for $120M in annual savings. Management maintained its full-year outlook.
Dentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.
BMO Capital maintained a 'Market Perform' rating for Dentsply Sirona (XRAY) but lowered its price target from $13.00 to $10.00, citing challenges in the healthcare sector. The stock is currently trading at $10.14, with a GF Value™ of $17.30, suggesting it is 41.4% undervalued. The company's GF Score™ is 55/100, indicating average performance across various metrics.
Recent XRAY coverage spans earnings, financial news and technology.
Dentsply Sirona reported a Q2 2026 profit of $37M, reversing a $45M loss from the prior year, despite a 4.1% sales decline to $898M. Gross margin improved to 54.9%, and operating cash flow doubled to $99M. The company's turnaround plan aims for $120M in annual savings. Management maintained its full-year outlook.
Dentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.
Analyst price target cut suggests near-term downside pressure.
Profitability improvement may attract value investors, but shrinking revenue and high short interest keep downside risk.
Positive trial data may boost confidence in Dentsply's implant segment and support near‑term price upside.
AlphAI scores every news story that mentions XRAY with an AI model for sentiment and relevance, and aggregates insider trades from DENTSPLY SIRONA Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dentsply Sirona reported a Q2 2026 profit of $37M, reversing a $45M loss from the prior year, despite a 4.1% sales decline to $898M. Gross margin improved to 54.9%, and operating cash flow doubled to $99M. The company's turnaround plan aims for $120M in annual savings. Management maintained its full-year outlook.
2 min readDentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.
2 min readBMO Capital maintained a 'Market Perform' rating for Dentsply Sirona (XRAY) but lowered its price target from $13.00 to $10.00, citing challenges in the healthcare sector. The stock is currently trading at $10.14, with a GF Value™ of $17.30, suggesting it is 41.4% undervalued. The company's GF Score™ is 55/100, indicating average performance across various metrics.
2 min readDentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.
3 min readDentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.
2 min readDentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.
6 min readDentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.
6 min readDentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.
3 min readDentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.
6 min readDentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 revenue of $898 million, down 4.1% year over year but 0.6% above market expectations. Full-year revenue guidance is $3.55 billion at the midpoint, about 1% below analysts’ estimates. Non-GAAP EPS was $0.52, 50.1% above consensus. Shares rose 1.8% to $13.42 after the release.
4 min read
